Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
BUSINESS
Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
Gilead Sciences is boosting its oncology business in Japan, centering on its anti-TROP-2 antibody drug conjugate (ADC) Trodelvy (sacituzumab govitecan) launched last year as well as CAR-T cell therapies, also with an eye on a sales force expansion. The company’s…
To read the full story
Related Article
- Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
- Expert Hails Japan Approval of Gilead’s Trodelvy for Triple-Negative Breast Cancer
October 30, 2024
- Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
- Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
BUSINESS
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Meiji Revives Penicillin Raw Material Production in Japan after 31 Years, Races to Pass Down Know-How
August 26, 2025
- Nippon Kayaku to Set Up Singapore-Based JV to License Drugs in Asia
August 26, 2025
- Dayvigo, Jardiance Heavily Promoted in July: Intage
August 26, 2025
- Japan Approves Roche Diagnostics Test for HER2 Ultralow Breast Cancer
August 26, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…